Stockscreener 앱 받기
78.59
1.69%
-1.35
시간 외 거래:
78.54
-0.05
-0.06%
전일 마감가:
$79.94
열려 있는:
$79.94
하루 거래량:
524.76K
Relative Volume:
0.95
시가총액:
$6.13B
수익:
$754.05M
순이익/손실:
$73.06M
주가수익비율:
86.62
EPS:
0.9073
순현금흐름:
$164.23M
1주 성능:
-1.49%
1개월 성능:
+1.25%
6개월 성능:
+73.41%
1년 성능:
+101.93%
1일 변동 폭
$76.88
$80.34
1주일 범위
$76.88
$82.98
52주 변동 폭
$35.20
$82.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
78.59 | 6.13B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-30 | 개시 | Wells Fargo | Overweight |
| 2026-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-09-29 | 개시 | TD Cowen | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Squarepoint Ops LLC Has $8.96 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Megna Michael R Reduces Kiniksa Holdings to 29,062 Shares Following Sale and Other Transactions - Kalkine Media
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.2% -- What GF Score of 46 Tells Investors - GuruFocus
Kiniksa Pharmaceuticals COO Moat Ross Executes Significant Equity Transactions on September 1, 2026 - Kalkine Media
Kiniksa sets a live healthcare talk for Sept. 9 - Stock Titan
Kiniksa Pharmaceuticals CEO Sanj K Patel Reports RSU Vesting, Share Sale, and New Equity Grants - Kalkine Media
Kiniksa CFO Mark Ragosa Reports RSU Vestings, Tax Withholding Share Sale, and New Equity Grants - Kalkine Media
Kiniksa (NASDAQ: KNSA) grants 14,600 options and 3,650 RSUs to Michael Megna - stocktitan.net
Kiniksa (NASDAQ: KNSA) grants CMO options and RSUs - stocktitan.net
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares - MarketBeat
Kiniksa Pharmaceuticals (KNSA) gives CEO new 10-year stock option grant - stocktitan.net
Kiniksa (KNSA) CEO gets new equity grants vesting over four years - stocktitan.net
Kiniksa Pharmaceuticals (KNSA) awards CFO new equity - stocktitan.net
Officer at Kiniksa (NASDAQ: KNSA) plans $369K stock sale - Stock Titan
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA - marketbeat.com
Kiniksa stock holds firm after a $243.6 million quarter - ad-hoc-news.de
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
Kiniksa (KNSA) Earnings Reading: The EPS Result Is Below Expectation in the Current Update; Share Move: The Market Price Advances 1.03% at the CloseProfitability Analysis - vinanet.vn
Kiniksa Director Barry D Quart Donates 2,600 Class A Shares to Donor Advised Fund - Kalkine Media
Kiniksa (NASDAQ: KNSA) director gifts 2,600 shares to donor fund - stocktitan.net
Kiniksa (KNSA) Earnings Report: EPS Comes in Below Forecast in the Reported Period; Trading Move: Shares Move 2.88% Lower on the DayEarnings Revision Downgrade - vinanet.vn
Kiniksa Pharmaceuticals International PLC - TradingKey
Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story - ChartMill
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 3. - GuruFocus
Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - sharewise.com
Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - Yahoo Finance
KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews
Kiniksa Pharmaceuticals (KNSA) Holds Near $76.53 as Bulls Eye $80.36 ResistanceBPI Bull Correction - vinanet.vn
Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat
Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang
Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - manilatimes.net
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - GlobeNewswire
Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat
Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews
Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kiniksa Pharmaceuticals International Plc 주식 (KNSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Megna Michael R | Officer |
Sep 03 '26 |
Proposed Sale |
80.30 |
4,600 |
369,380 |
0 |
| Cole G Bradley | Director |
Jul 29 '26 |
Proposed Sale |
81.43 |
3,673 |
299,092 |
0 |
| Tessari Eben | Former Affiliate |
Jul 29 '26 |
Proposed Sale |
79.74 |
67,062 |
5,347,344 |
0 |
| Cole G Bradley | Director |
Jul 29 '26 |
Sale |
81.43 |
3,673 |
299,092 |
11,672 |
| Patel Sanj K | CHAIRMAN & CEO |
May 01 '26 |
Option Exercise |
30.93 |
48,565 |
1,502,115 |
48,565 |
| Paolini John F. | CHIEF MEDICAL OFFICER |
May 01 '26 |
Option Exercise |
10.36 |
58,424 |
605,273 |
124,047 |
| Paolini John F. | CHIEF MEDICAL OFFICER |
May 01 '26 |
Sale |
53.71 |
58,424 |
3,137,823 |
65,623 |
| Paolini John F. | Officer |
May 01 '26 |
Proposed Sale |
53.71 |
58,424 |
3,137,710 |
0 |
| Patel Sanj K | CHAIRMAN & CEO |
May 01 '26 |
Sale |
54.02 |
48,565 |
2,623,481 |
0 |
| Patel Sanj K | CHAIRMAN & CEO |
Apr 30 '26 |
Sale |
54.01 |
2,141 |
115,635 |
0 |
0.29%
2.79%
자본화:
|
볼륨(24시간):